These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34484217)

  • 21. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer.
    Barua S; Fang P; Sharma A; Fujimoto J; Wistuba I; Rao AUK; Lin SH
    Lung Cancer; 2018 Mar; 117():73-79. PubMed ID: 29409671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiRNA-200a expression is inverse correlation with hepatocyte growth factor expression in stromal fibroblasts and its high expression predicts a good prognosis in patients with non-small cell lung cancer.
    Chen Y; Du M; Wang J; Xing P; Zhang Y; Li F; Lu X
    Oncotarget; 2016 Jul; 7(30):48432-48442. PubMed ID: 27374174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
    Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
    Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer.
    Guo X; Shi J; Wen Y; Li M; Li Q; Li X; Li J
    Cancer Biomark; 2018 Feb; 21(3):547-555. PubMed ID: 29278873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
    Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer.
    Dai F; Liu L; Che G; Yu N; Pu Q; Zhang S; Ma J; Ma L; You Z
    BMC Cancer; 2010 May; 10():220. PubMed ID: 20487543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.
    Usó M; Jantus-Lewintre E; Bremnes RM; Calabuig S; Blasco A; Pastor E; Borreda I; Molina-Pinelo S; Paz-Ares L; Guijarro R; Martorell M; Forteza J; Camps C; Sirera R
    Oncotarget; 2016 Aug; 7(33):52849-52861. PubMed ID: 27463005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified.
    Ota T; Kirita K; Matsuzawa R; Udagawa H; Matsumoto S; Yoh K; Niho S; Ishii G; Goto K
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2495-2506. PubMed ID: 31494736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
    La Fleur L; Boura VF; Alexeyenko A; Berglund A; Pontén V; Mattsson JSM; Djureinovic D; Persson J; Brunnström H; Isaksson J; Brandén E; Koyi H; Micke P; Karlsson MCI; Botling J
    Int J Cancer; 2018 Oct; 143(7):1741-1752. PubMed ID: 29667169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer.
    Ahn H; Lee HJ; Lee JH; Cho HD; Oh MH; Son JW; Jang SH
    Pathol Res Pract; 2020 Nov; 216(11):153188. PubMed ID: 32919305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-cell and spatial transcriptomics reveal POSTN
    Chen C; Guo Q; Liu Y; Hou Q; Liao M; Guo Y; Zang Y; Wang F; Liu H; Luan X; Liang Y; Guan Z; Li Y; Liu H; Dong X; Zhang X; Liu J; Xu Q
    Clin Transl Med; 2023 Dec; 13(12):e1515. PubMed ID: 38115703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma.
    Sakai T; Aokage K; Neri S; Nakamura H; Nomura S; Tane K; Miyoshi T; Sugano M; Kojima M; Fujii S; Kuwata T; Ochiai A; Iyoda A; Tsuboi M; Ishii G
    Lung Cancer; 2018 Dec; 126():64-71. PubMed ID: 30527194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.
    Montero MA; Aricak O; Kis L; Yoshikawa A; De Petris L; Grundberg O; Pham HHN; Roden AC; Fukuoka J; Attanoos R; Guijarro R; Alarcón F; Lindström K; Ortiz-Villalón C
    Ann Diagn Pathol; 2021 Apr; 51():151701. PubMed ID: 33485052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. APE1 may influence CD4+ naïve T cells on recurrence free survival in early stage NSCLC.
    Li Y; Zhao X; Xiao H; Yang B; Liu J; Rao W; Dai X; Li M; Dai N; Yang Y; Wang D
    BMC Cancer; 2021 Mar; 21(1):233. PubMed ID: 33676448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.